Michael C. Soulen, MD of the University of Pennsylvania discusses that peptide receptor radionuclide therapy US approval expected early 2018 from ASCO GI 2018.
Michael C. Soulen, MD of the University of Pennsylvania discusses that peptide receptor radionuclide therapy US approval expected early 2018 from ASCO GI 2018.